Top

Published in:

01-03-2015 | Research Article

Impact of MDM2 gene polymorphism on sarcoma risk

Authors: Dawei Zhang, Yuanyuan Ding, Zhenlin Wang, Yan Wang, Guangyue Zhao

Published in: Tumor Biology | Issue 3/2015

Abstract

A T>G single nucleotide polymorphism (SNP, rs2279744) of the MDM2 gene has been investigated in sarcoma community, but the findings are conflicting. This study was designed to well define the relationship between SNP rs2279744 and sarcoma risk. We did a systematic computerized search of the PubMed, Web of Science, and Science Direct databases to identify the human case–control studies investigating the relationship between SNP rs2279744 and sarcoma risk with complete genetic data. Pooled odds ratios (ORs) were calculated with the Mantel–Haenszel fixed-effect model or the DerSimonian and Laird random effects model to estimate the risk of sarcoma. Overall analysis included five independent studies. On the whole, the T/G genotype or the combined G/G and T/G genotypes appeared to be associated with approximately 1.40-fold higher risk of sarcoma relative to the T/T genotype (T/G vs. T/T: OR 1.33, 95 % CI 1.00–1.77; G/G + T/G vs. T/T: OR 1.42, 95 % CI 1.08–1.85). We noted that the Caucasian populations showed a similarly increased risk of sarcoma ascribed to the carriage of the same genotypes (T/G vs. T/T: OR 1.41, 95 % CI 1.05–1.90; G/G + T/G vs. T/T: OR 1.49, 95 % CI 1.13–1.97). This meta-analysis provides evidence that MDM2 SNP rs2279744 may be significantly associated with increased risk of sarcoma in Caucasian individuals.

Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(1 Suppl):203–10.CrossRefPubMed

Borden EC et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003;9(6):1941–56.PubMed

Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49–53.CrossRefPubMed

Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101–28.CrossRefPubMed

Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1(14):1001–8.PubMed

Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95–107.CrossRefPubMed

Huang SF et al. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2009;45(1):16–22.CrossRefPubMed

Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13(1):49–58.CrossRefPubMed

Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev. 2006;20(2):125–31.CrossRefPubMed

10.

Greenblatt MS et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(18):4855–78.PubMed

11.

Jones SN et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998;95(26):15608–12.CrossRefPubMedPubMedCentral

12.

Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein–thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1999;59(1):1–7.PubMed

13.

Bond GL et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.CrossRefPubMed

14.

Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65(13):5481–4.CrossRefPubMed

15.

Thurow HS et al. Ewing sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Mol Biol Rep. 2013;40(8):4929–34.CrossRefPubMed

16.

Tornesello ML et al. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients. Biomarkers. 2011;16(1):42–50.CrossRefPubMed

17.

Toffoli G et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15(10):3550–6.CrossRefPubMed

18.

Alhopuro P et al. The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42(9):694–8.CrossRefPubMedPubMedCentral

19.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed

20.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:15–7.

21.

Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443–57.CrossRefPubMed

22.

Leach FS et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10 Suppl):2231–4.PubMed

23.

Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96–107.CrossRefPubMed

24.

Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2(1):1–8.PubMed

25.

Oliner JD et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80–3.CrossRefPubMed

26.

Cordon-Cardo C et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54(3):794–9.PubMed

27.

Birgander R et al. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46(3):148–54.CrossRefPubMed

28.

Arva NC et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280(29):26776–87.CrossRefPubMed

29.

Ruijs MW et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007;15(1):110–4.CrossRefPubMed

30.

Cai X, Yang M. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol. 2012;138(4):555–61.CrossRefPubMed

Title: Impact of MDM2 gene polymorphism on sarcoma risk
Authors: Dawei Zhang
Yuanyuan Ding
Zhenlin Wang
Yan Wang
Guangyue Zhao
Publication date: 01-03-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2781-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

RAB34 was a progression- and prognosis-associated biomarker in gliomas

Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42

ARNT2 is downregulated and serves as a potential tumor suppressor gene in non-small cell lung cancer

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway

Circulating microRNA-21 as a biomarker for the detection of various carcinomas: an updated meta-analysis based on 36 studies

Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer